Ignite Creation Date:
2024-05-05 @ 5:24 PM
Last Modification Date:
2024-10-26 @ 9:31 AM
Study NCT ID:
NCT00442845
Status:
COMPLETED
Last Update Posted:
2021-02-18
First Post:
2007-02-28
Brief Title:
Establish The Benefits Of Using Various Starting Doses Of Atorvastatin On Achievement Of Cholesterol Targets ACTFAST
Sponsor:
Pfizers Upjohn has merged with Mylan to form Viatris Inc
Organization:
Pfizer
Study Overview
Official Title:
ACTFAST Achieve Cholesterol Targets Fast With Atorvastatin Stratified Titration A Multicenter Twelve-Week Treatment Single Step Titration Open-Label Study Assessing The Percentage Of Dyslipidemic High-Risk Patients Achieving Low Density Lipoprotein Cholesterol LDL-C Target With Atorvastatin Starting Doses Of 10 Mg 20 Mg 40 Mg And 80 Mg
Status:
COMPLETED
Status Verified Date:
2021-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
ACTFAST
Brief Summary:
Physicians tend to always use the lowest dose of statins to initiate therapy even in subjects who require large reductions in cholesterol The study evaluates if selecting the starting dose based on baseline and target LDL-C cholesterol would provide better results ie proportion of subjects resching target
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None